Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

BioVie building healthier future for families and caregivers dealing with neurodegenerative diseases

BioVie Inc

BioVie Chief Social Impact Officer Sarah Hoit joined Proactive's Natalie Stoberman to bring more awareness to Alzheimer's and Brain Awareness month. Hoit shared how the company's initiatives are trying to positively impact the families and caregivers, as well as finding alternatives to ease the stress of neurodegenerative diseases on the healthcare system and the economy. Hoit said BioVie continues to create more impact investment opportunities with new trials and initiatives on the horizon. But most importantly, Hoit said the growth of BioVie's Social Impact Partners Foundation has been growing to create a global consortium of leaders and organizations to impact brain health and create a healthier future through fundraising, resource mobilization and industry collaboration. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

June 28, 2023 12:59 PM Eastern Daylight Time

Video

Living with Myasthenia Gravis: The Rare Autoantibody Disease That Causes Muscle Weakness and Severe Fatigue

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/-FuYn9PdBdI What would you do if you began to have symptoms of drooping eyelids and difficulty speaking? A rare and unfamiliar condition that turned to a daily struggle to chew, swallow, smile, see, or even lift your arms, legs, and neck. That is what happened to Meridith O’Connor at the age of 13 and after two long years of doctor visits, she was finally diagnosed with myasthenia gravis, also known as MG. Myasthenia gravis is a chronic autoantibody condition of the nervous system that affects muscle strength and makes everyday activities like standing, blinking, swallowing, and moving your arms challenging. MG is a highly debilitating rare disease for which there currently is no cure. As many as 60,000 Americans, and 700,000 people worldwide are living with the condition. June is Myasthenia Gravis Awareness Month, which provides an opportunity for people around the world to recognize the impact of MG. On June 26th a media tour was conducted with Meridith O’Connor, Assistant Vice President of Patient Engagement, Advocacy, and Policy for the Myasthenia Gravis Foundation of America (MGFA), and Dr. Nicholas Silvestri, an associate professor of neurology at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, to learn the latest on the disease and how it affects those living with it. Approximately 85% of people living with MG experience the more extensive form of the disease, generalized myasthenia gravis (gMG). MG affects both men and women and occurs across all ages and racial and ethnic groups. However, it most commonly impacts young adult women and older men. Diagnosis is often a long, frustrating, and painful journey for patients. This is because muscle weakness is a common symptom of many disorders, and symptoms can fluctuate. Patients often face months or years of untreated symptoms before they receive an accurate diagnosis, which is why they are often diagnosed at an older age. Despite availability of treatment options, significant unmet need persists, as up to 20% of patients do not respond to existing treatments and are left with no effective therapeutic options. Research is needed to develop new treatments for those who may not respond well and/or tolerate current therapies. FOR MORE INFORMATION VISIT: IMAGINEMYMG.COM THIS MEDIA TOUR IS BROUGHT TO YOU BY THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 28, 2023 10:02 AM Eastern Daylight Time

Video

Chill Brands Group CEO takes aim at "moral panic" around vaping

Chill Brands Group PLC

Chill Brands Group PLC (LSE:CHLL, OTCQB:CHBRF) CEO Callum Sommerton speaks to Thomas Warner from Proactive about recent additions to the product range on offer at Chill.com, the performance of the business during the first half of calendar year 2023 and his hopes for the coming months. He reiterates his commitment to launching nicotine-free vapes in the UK market, saying that "the second half of this year is all about that activation", and says Chill Brands is "proving wrong the doubters in relation to what I suggest is a moral panic around vaping that's happening in the UK at the moment." Chill is already marketing nicotine-free vapes in the US, and Sommerton says that he's already "getting great data from our US pilot stores." Contact Details UK Editorial +44 20 7989 0813 uk@proactiveinvestors.com

June 28, 2023 08:08 AM Eastern Daylight Time

Video

Creo Medical Group gets "great results" from first upper GI use of Speedboat Inject in Europe

Creo Medical Group PLC

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after the medical device company announced that the first upper gastrointestinal (GI) procedure in Europe has been carried out using the company's Speedboat Inject product. Gulliford says that the procedure to remove a cancer from a patient's stomach was successfully completed by Adolfo Parra-Blanco at Nottingham University Hospitals, with the "great results... we've come to expect." Gulliford also explains why Creo is now looking for a new Chairman to help develop the company internationally. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 28, 2023 08:05 AM Eastern Daylight Time

Video

hVIVO to develop first commercial hMPV human challenge model

hVIVO PLC

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after announcing that the specialist contract research organisation has partnered with a North American biopharmaceutical company to create the industry's first commercial hMPV human challenge model. Khan says he's "very happy with the signing of this contract" before going to explain the significance of the news for hVIVO investors as well as for patients. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 28, 2023 07:42 AM Eastern Daylight Time

Video

ImmuPharma "absolutely delighted" to push on with new clinical trial

ImmuPharma PLC

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that the specialty biopharmaceutical will be moving forward into a key phase 2/3 adaptive clinical trial, alongside its US partners Avion Pharmaceuticals. McCarthy says that he's "absolutely delighted" to be moving forward with the study and emphasises the significant potential of its deal with Avion, including milestone payments of up to $70 million and double-digit royalty percentages, in addition to obvious benefit to patients. McCarthy also mentions ongoing discussions for more commercial partnerships and the potential for major breakthroughs in the future. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 28, 2023 07:37 AM Eastern Daylight Time

Video

'Siblings of the Exceptional’: Empowering Siblings of the Special Needs Children And Creating Lasting Impact

Siblings of the Exceptional

'Siblings of the Exceptional,' an organization dedicated to supporting siblings of special needs children, is making a significant difference in the community. Founded by Reema Patel, a 14-year-old American girl and rising sophomore, the organization focuses on raising awareness, providing resources and fostering inclusion for siblings of individuals with Cerebral Palsy and other special needs as well as their families. By emphasizing the organization’s goals and achievements it brings positive changes to the community and showcases the collective effort in supporting siblings of special needs. This approach allows them to promote a cause and create awareness about siblings of special needs within the community. According to recent statistical data by WHO, an estimated 1.3 billion people - or 16% of the global population worldwide - experience a significant disability today. People with disabilities have the right to the highest attainable standard of health as those without disabilities. However, the WHO Global report on health equity for people with disabilities demonstrates that while some progress has been made in recent years, the world is far from realizing this right for many people with disabilities, because they continue to die earlier, have worse health, and experience more limitations in everyday functioning than others. These poor health outcomes are due to unfair conditions faced by people with disabilities in all facets of life, including the health system in many countries. Countries have an obligation under international human rights law to address the health inequities faced by people with disabilities. Furthermore, the Sustainable Development Goals and global health priorities will not progress without ensuring health for all. Recognizing the significance of these numbers and the impact on families, Reema took it upon herself to provide a platform for siblings of these exceptional children to connect, share experiences, and find solace in a nurturing community. Through the efforts of 'Siblings of the Exceptional,' strides are being made to address these statistics, improve the lives of special needs children as well as their siblings and promote a more inclusive society. The Initiative to Bond special needs with Their Siblings ‘Siblings of the Exceptional' also focuses on fostering a special bond among special needs children and their siblings. Recognizing the importance of these relationships, the organization arranges events and programs that promote a stronger bond between the children with special needs and their siblings. By doing so, they create a supportive and inclusive environment for special needs and their families. The latest event took place on June 24th, 2023 in Pune, India where a generous amount of resources were donated by Reema Patel to the Buddy Center institute which is an initiative by Kunashini. The esteemed chief Guest, Dr Archana Kadam, praised Reema Patel's extraordinary efforts and offered valuable insights on raising awareness about Cerebral palsy and special needs. The event served as a platform to foster a sense of community and create lasting memories. Fundraising Efforts To date, 'Siblings of the Exceptional' has successfully raised approximately US $9,740. These funds have been instrumental in supporting numerous NGOs in India that work tirelessly to meet the basic needs of special needs children, providing them with vital resources, therapies, and a nurturing environment. This highlights the impact and effectiveness of the organization's fundraising efforts. The World too can join the Cause of 'Siblings of the exceptional". The dynamic Reema Patel passionately appeals to individuals, organizations, and a wider community to support the noble causes of 'Siblings of the Exceptional.' Donations and fundraising efforts play a pivotal role in enabling the provision of essential resources and services to special needs children in need. By contributing to the cause, you can make a tangible difference in their lives. To learn more about this inspiring journey, contribute to her cause, or participate in upcoming events, please visit 'Siblings of the Exceptional' at https://www.siblingsoftheexceptional.com/. Contact Details Siblings of the Exceptional Reema Patel +1 540-558-8784 dreamsforspecialfamilies@gmail.com Company Website https://www.siblingsoftheexceptional.com/

June 27, 2023 11:00 AM Eastern Daylight Time

DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement

DSS, Inc.

By David Willey, Benzinga DSS, Inc. (NYSE American: DSS) is finalizing the long-anticipated spin-off of its biotech subsidiary, Impact Biomedical, Inc. The spin-off will reward DSS investors with shares from Impact, and it will come after an Impact subsidiary signed a licensing agreement with a pharmaceutical company. Investors who own DSS shares as of June 30 will receive four (4) Impact Biomedical shares for every one of their DSS shares, as part of the spin-off. The spin-off is coming after Impact Biomedical’s subsidiary, Global BioLife, Inc., signed a licensing agreement with ProPhase BioPharma, Inc., a subsidiary of ProPhase Labs, Inc. (NASDAQ: PRPH) for Global BioLife’s Linebacker portfolio of treatments, LB-1 and LB-2. Prophase Labs is a growing diagnostic, genomics and biotech company with a diversified portfolio. Impact’s Success In Biotech Linebacker is a platform of small molecule X-bonded polyphenols, and LB-1 and LB-2 are treatments that are expected to be effective in crossing the blood-brain barrier. Linebacker could prove to be a treatment with a range of applications, including in neurology, anti-inflammatory and oncology diseases. With this licensing agreement, ProPhase will continue developing Linebacker as a potential therapeutic. In fact, on June 1, ProPhase announced that “Harvard scientists at the Dana Farber Cancer Institute, in two separate lung and colon cancer clonogenic models, have successfully demonstrated Linebacker’s ability to inhibit cancer cell growth, an exciting development for the polyphenol compound.” The company already believes that LB-1 may be an effective therapy for hard-to-treat cancers and other types of cancer. Frank D. Heuszel, CEO of DSS, commented on the agreement, “The execution of this licensing agreement represents a significant milestone for Impact BioMedical and its robust portfolio of development opportunities. This is the second license agreement with ProPhase this year, and we are excited to deepen our work together as they apply their nearly three decades of experience enhancing the health of the public.” Ted Karkus, ProPhase Lab's CEO, commented on the partnership in July 2022, “We believe the Linebacker platform has multi-billion-dollar potential in oncology as well as significant potential in other fields.” 4 Shares In Spin-Off For Every DSS Share DSS could offer a potentially lucrative opportunity to investors looking to diversify their portfolios. This is not the only spin-off opportunity that DSS will offer, as the company operates nine divisions and 40 subsidiaries. DSS has plans to spin off two other of its successful subsidiaries later in 2023. These are the medical real estate investment trust, AAMI/AMRE, as well as the financial services company, American Pacific Bancorp. By incubating and eventually spinning off companies, DSS develops companies like Impact Biomedical to increase shareholder value. All shareholders of record on June 30, will receive four (4) shares in Impact Biomedical to be distributed on July 14. Learn more about what DSS, Inc. is doing to support and spinoff businesses. DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details Rick Lutz- TraDigital IR rick@tradigitalir.com Company Website https://www.dssworld.com/

June 27, 2023 09:15 AM Eastern Daylight Time

Roquefort Therapeutics "seeing good results" across several therapeutics

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive following a flurry of announcements from the biotech company. Reginald gives an overview of three recent developments, including the results of trials into treatments for osteosarcoma and Midkine-expressing cancers. He also highlights recent increases in the level of investment in the company by himself and by executive chairman Stephen West. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 27, 2023 08:32 AM Eastern Daylight Time

Video

1 ... 111 112 113 114 115 ... 306